Current therapeutic options for Huntington's disease: Good clinical practice versus evidence-based approaches?

Movement Disorders

Volumn 29, Issue 11, 2014, Pages 1404-1413

  Killoran, Annie ^a   Biglan, Kevin M ^b  

^a WEST VIRGINIA UNIVERSITY   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Evidence based medicine; Expert opinion; Huntington's disease; Treatment

Indexed keywords

COGNITION DISORDERS; COMPLICATION; EVIDENCE BASED MEDICINE; HUMAN; HUNTINGTON DISEASE; MENTAL DISORDERS; MOVEMENT DISORDERS;

COGNITION DISORDERS; EVIDENCE-BASED MEDICINE; HUMANS; HUNTINGTON DISEASE; MENTAL DISORDERS; MOVEMENT DISORDERS;

EID: 84907931175     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26014     Document Type: Review

References (181)

1. Burgunder JM, Guttman M, Perlman S, et al. An international survey-based algorithm for the pharmacologic treatment of chorea in Huntington's disease. PLoS Curr 2011;3:RRN1260.
2. Adam OR, Jankovic J. Symptomatic treatment of Huntington disease. Neurotherapeutics 2008;5:181-197.
3. Frank S. Treatment of Huntington's disease. Neurotherapeutics 2014;11:153-160.
4. Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn't. BMJ 1996;312:71-72.
5. Armstrong MJ, Miyasaki JM. Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology 2012;79:597-603.
6. Cochrane AL. Effectiveness and Efficiency: Random Reflections on Health Services. London: Nuffeld Provincial Hospitals Trust, 1972.
7. Labrecque M, Cauchon M. Is evidence-based medicine overrated in family medicine? No. Can Fam Physician 2013;59:1162-1163.
8. Labrecque M, Hay MC, Weisner TS, et al. Harnessing experience: exploring the gap between evidence-based medicine and clinical practice. J Eval Clin Pract 2008;14:707-713.
9. Tonelli MR. The limits of evidence-based medicine. Respir Care 2001;46:1435-1440; discussion 1440- 1441.
10. Qaseem A. A perspective on the guidelines international network and the institute of medicine's proposed standards for guideline development. [Internet] Maryland: Agency for Healthcare Research and Quality;2013 Apr 8. [cited 2014 Month 04]. Available from: http://www.guideline.gov/expert/expert-commentary.aspx?id=43913.
11. Jacobson JO, Wolff AC. Evidence-based medicine: do clinical practice guidelines contribute to better patient care? Medscape. [cited 2014 Month 04]. Accessed April 2014. Available from: http://www.medscape.org/viewarticle/589088.
12. Feinstein AR, Horwitz RI. Problems in the "evidence" of "evidence-based medicine". Am J Med 1997;103:529-535.
13. Mestre T, Ferreira J, Coelho MM, Rosa M, Sampaio C. Therapeutic interventions for symptomatic treatment in Huntington's disease. Cochrane Database Syst Rev 2009;3:CD006456.
14. Mestre TA, Ferreira JJ. An evidence-based approach in the treatment of Huntington's disease. Parkinsonism Relat Dis 2012;18:316-320.
15. Killoran A, Biglan KM. Therapeutics in Huntington's disease. Curr Treat Options Neurol 2012;14:137-149.
16. Videnovic A. Treatment of Huntington disease. Curr Treat Options Neurol 2013;15:424-438.
17. Venuto CS, McGarry A, Ma Q, et al. Pharmacologic approaches to the treatment of Huntington's disease. Mov Disord 2012;27:31-41.
18. Novak MJ, Tabrizi SJ. Huntington's disease: clinical presentation and treatment. Int Rev Neurobiol 2011;98:297-323.
19. Frank S, Jankovic J. Advances in the pharmacological management of Huntington's disease. Drugs 2010;70:561-571.
20. Phillips W, Shannon KM, Barker RA. The current clinical management of Huntington's disease. Mov Disord 2008;23:1491-1504.
21. Groves M, van Duijn E, Anderson K, et al. An international survey-based algorithm for the pharmacologic treatment of irritability in Huntington's disease. PLoS Curr 2011;3:RRN1259.
22. Anderson K, Craufurd D, Edmondson MC, et al. An international survey-based algorithm for the pharmacologic treatment of obsessive-compulsive behaviors in Huntington's Disease. PLoS Curr 2011;3:RRN1261.
23. Eibling D, Fried M, Blitzer A, Postma G. Commentary on the role of expert opinion in developing evidence-based guidelines. Laryngoscope 2014;124:355-357.
24. Gupta M. Does evidence-based medicine apply to psychiatry? Theor Med Bioeth 2007;28:103-120.
25. Duggal R, Menkes DB. Evidence-based medicine in practice. Int J Clin Pract 2011;65:639-644.
26. Straus S, Richardson WS, Glasziou P, Haynes RB. Evidence-Based Medicine: How to Practice and Teach EBM (3rd ed.). Edinburgh: Churchill Livingstone, 2005 [4th ed.: 2011].
27. Möller HJ. Is evidence sufficient for evidence-based medicine? Eur Arch Psychiatry Clin Neurosci 2009;259[Suppl 2]:S167-S172.
28. Watters WC. Clinical guidelines strengthened by evidence-based practice. American Academy of Orthopedic Surgeons. April 2014. Available from: http://www.aaos.org/news/bulletin/janfeb07/research4.asp.
29. Lucas MG, Bosch RJ, Burkhard FC, et al. European Association of Urology EAU guidelines on surgical treatment of urinary incontinence. Eur Urol 2012;62:1118-1129.
30. Johnson SG, Kayser SR, Attridge RL, et al. Key articles and guidelines in the management of pulmonary arterial hypertension: 2011 update. Pharmacotherapy 2012;32:e134-e169.
31. Cobaugh DJ, Erdman AR, Booze LL, et al. Atypical antipsychotic medication poisoning: an evidence-based consensus guideline for out-of-hospital management. Clin Toxicol (Phila) 2007;45:918-942.
32. Gauthier L, Almeida F, Arcache JP, et al. Position paper by Canadian dental sleep medicine professionals on the role of different health care professionals in managing obstructive sleep apnea and snoring with oral appliances. Can Respir J 2012;19:307-309.
33. Palareti G, Ageno W, Ferrari A, et al. Clinical management of rivaroxaban-treated patients. Expert Opin Pharmacother 2013;14:655-667.
34. Dunselman GA, Vermeulen N, Becker C, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod 2014;29:400-412.
35. Springer SC, Silverstein J, Copeland K, et al. American Academy of Pediatrics. Management of type 2 diabetes mellitus in children and adolescents. Pediatrics 2013;131:e648-e664.
36. Worthington I, Pringsheim T, Gawel MJ, et al. Canadian Headache Society Acute Migraine Treatment Guideline Development Group. Canadian Headache Society Guideline: acute drug therapy for migraine headache. Can J Neurol Sci 2013;40(5 Suppl 3):S1-S80.
37. Alexopoulos GS, Jeste DV, Chung H, Carpenter D, Ross R, Docherty JP. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary. Postgrad Med 2005;Spec No:6-22.
38. Llorca PM, Abbar M, Courtet P, Guillaume S, Lancrenon S, Samalin L. Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry 2013;20:13:340.
39. American Psychiatric Association. [cited February 2014]. Available from:.http://www.psych.org/practice/clinical-practice-guidelines/Expert-Opinion-Panels
40. American Medical Association. [cited February 2014]. Available from: http://www.ama-.assn.org/resources/doc/PolicyFinder/policyfiles/HnE/H-410.953.HTM
41. Kaplan BJ, Giesbrecht G, Shannon S, McLeod K. Evaluating treatments in health care: the instability of a one-legged stool BMC Med Res Methodol 2011;11:65.
42. Haynes RB, Devereaux PJ, Guyatt GH. Physicians' and patients' choices in evidence-based practice. BMJ 2002;324:1350.
43. Straus S, Haynes B, Glasziou P, Dickersin K, Guyatt G. Misunderstandings, misperceptions, and mistakes. ACP J Club 2007;146:A8-A9.
44. Reilmann R. Pharmacological treatment of chorea in Huntington's disease: good clinical practice versus evidence-based guideline. Mov Disord 2013;28:1030-1033.
45. Goodman L. The flaw in the AAN Chorea Guidelines. Huntington's Disease Drug Works. [cited 2012 July 23]. Available from: http://hddrugworks.org/index.php?option=com_content&task=view&id=312.
46. Vetter L. American Academy of Neurology [letter]. [cited 2012 July 9]. Available from: http://www.hdsa.org/images/content/1/7/17235/2012-07-06%20AAN%20letter%20to%20HDSA.PDF
47. Hamilton J, Wolfson T, Peavy G, Jacobson M, Corey-Bloom J. Rate and correlates of weight change in Huntington's disease. J Neurol Neurosurg Psychiatry 2004;75:209-212.
48. Shen V, Clarence-Smith K, Hunter C, Jankovic J. Safety and efficacy of tetrabenazine and use of concomitant medications during long-term, open-label treatment of chorea associated with Huntington's and other diseases. Tremor Other Hyperkinet Mov 2013;3. PMCID: PMC3822048.
49. Briefing Memo Food and Drug Aministration. [cited 2007 December 6]. Available from: http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4328b1-01-FDA.pdf
50. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006;66:366-372.
51. Hamilton JM, Salmon DP, Corey-Bloom J, et al. Behavioural abnormalities contribute to functional decline in Huntington's disease. J Neurol Neurosurg Psychiatry 2003;74:120-122.
52. Van Vugt JPP, Siesling S, Vergeer M, van der Velde EA, Roos RAC. Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study. J Neurol Neurosurg Psychiatry 1997;63:3539.
53. Frank S. Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study: Huntington Study Group/TETRA-HD Investigators. BMC Neurol 2009;9:62.
54. Mahant N, McCusker EA, Byth K, Graham S, Huntington Study Group. Huntington's disease: clinical correlates of disability and progression. Neurology 2003;61:1085-1092.
55. Young AB, Shoulson I, Penney JB, et al. Huntington's disease in Venezuela: neurologic features and functional decline. Neurology 1986;36:244-249.
56. Penney JB Jr, Young AB, Shoulson I, et al. Huntington's disease in Venezuela: 7 years of follow-up on symptomatic and asymptomatic individuals. Mov Disord 1990;5:93-99.
57. McCusker EA, Gunn DG, Epping EA, et al. Unawareness of motor phenoconversion in Huntington disease. Neurology 2013;81:1141-1147.
58. Vitale C, Pellecchia MT, Grossi D, et al. Unawareness of dyskinesias in Parkinson's and Huntington's diseases. Neurol Sci 2001;22:105-106.
59. Sitek EJ, Soldtan W, Wieczorek D, et al. Self-awareness of motor dysfunction in patients with Huntington's disease in comparison to Parkinson's disease and cervical dystonia. J Int Neuropsychol Soc 2011;17:788-795.
60. Snowden JS, Craufurd D, Griffiths HL, Neary D. Awareness of involuntary movements in Huntington disease. Arch Neurol 1998;55:801-805.
61. Fasano A, Cadeddu F, Guidubaldi A, et al. The long-term effect of tetrabenazine in the management of Huntington disease. Clin Neuropharmacol. 2008;31:313-318.
62. Désaméricq G, Dolbeau G, Verny C, et al. 2014. Effectiveness of anti-psychotics and related drugs in the Huntington speaking group cohort. PLoS ONE 9 e85430.
63. Scott LJ. Tetrabenazine: for chorea associated with Huntington's disease. CNS Drugs 2011;25:1073-1085.
64. Du X, Pang TYC, Hannan AJ. A tale of two maladies? Pathogenesis of depression with and without the Huntington's disease gene mutation. Front Neurol 2013;4:81.
65. Marder K, Zhao RH, Myers M, et al. Rate of functional decline in Huntington's disease. Neurology 2000;54:452-458.
66. Ho AK, Gilbert AS, Mason SL. Health-related quality of life in Huntington's disease: which factors matter most? Mov Disord 2009;24:574-578.
67. Hubers AA, Reedeker N, Giltay EJ, Roos RA, van Duijn E, van der Mast RC. Suicidality in Huntington's disease. J Affect Disord 2012;136:550-557.
68. Farrer LA. Suicide and attempted suicide in Huntington disease: implications for preclinical testing of persons at risk. Am J Med Genet 1986;24:305-311.
69. Beglinger LJ, O'Rourke JJF, Wang C, Langbehn DR, Duff K, Paulsen JS. Earliest functional declines in Huntington disease. Psychiatry Res. 2010;178:414-418.
70. Xenazine [package insert]. Deerfield, IL: Lundbeck. Revised 2012. [cited 2014 July 9]. Available from: http://www.lundbeck.com/upload/us/files/pdf/Products/Xenazine_PI_US_EN.pdf
71. Heemskerk A, Roos RAC. Aspiration pneumonia and death in Huntington's disease. PLoS Curr 2012;Version 2.
72. O'Suilleabhain P, Dewey RB Jr. A randomized trial of amantadine in Huntington disease. Arch Neurol 2003;60:996-998.
73. Ory-Magne F, Corvol JC, Azulay JP, et al. Withdrawing amantadine in dyskinetic patients with Parkinson disease: the AMANDYSK trial. Neurology 2014;82:300-307.
74. Hubsher G, Haider M, Okun MS. Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology 2012;78:1096-1099.
75. Verhagen ML, Morris MJ, Farmer C, et al. Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology 2002;59:694-699.
76. Landwehrmeyer GB, Dubois B, Garcia de Ye'benes J, et al. Riluzole in Huntington's disease: a 3- year, randomized controlled study. Ann Neurol 2007;62:262-272.
77. Huntington Study Group. Dosage effects of riluzole in Huntington's disease: a multicenter placebo- controlled study. Neurology 2003;61:1551-1556.
78. Tetrabenazine drug monograph. Food and Drug Administration. [cited 2014 February]. Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=1308.12.
79. Curtis A, Mitchell I, Patel S, Ives N, Rickards H. A pilot study using nabilone for symptomatic treatment in Huntington's disease. Mov Disord 2009;24:2254-2259.
80. Gassull MA. Relevant end-points and outcome variables. What can we learn from the Editor? Evidence-based medicine in clinical nutrition. Symposium. 23rd Congress of the European Society for Parenteral and Enteral Nutrition Munich. 9-12 September 2001.
81. Laks J, Rocha M, Capitão C, et al. Functional and motor response to low dose olanzapine in Huntington's disease: case report. Arq Neuropsiquiatr 2004;62:1092-1094.
82. Johnston TG. Risperidone long-acting injection and Huntington's disease: case series with significant psychiatric and behavioural symptoms. Int Clin Psychopharmacol 2011;26:114-119.
83. Dallocchio C, Buffa C, Tinelli C, Mazzarello P. Effectiveness of risperidone in Huntington chorea patients. J Clin Psychopharmacol 1999;19:101-103.
84. Duff K, Beglinger LJ, O'Rourke ME, et al. Risperidone and the treatment of psychiatric, motor, and cognitive symptoms in Huntington's disease. Ann Clin Psychiatry 2008;20:1-3.
85. Johnston TG. Risperidone long-acting injection and Huntington's disease: case series with significant psychiatric and behavioural symptoms. Int Clin Psychopharmacol 2011;26:114-119.
86. Cankurtaran ES, Ozalp E, Soygur H, Cakir A. Clinical experience with risperidone and memantadine in the treatment of Huntington's disease. J Natl Med Assoc 2006;98:1353-1355.
87. Erdemoglu AK, Boratav C. Risperidone in chorea and psychosis of Huntington's disease. Eur J Neurol 2002;9:182-183.
88. Madhusoodanan S, Brenner R, Moise D, Sindagi J, Brafman I. Psychiatric and neuropsychological abnormalities in Huntington's disease: a case study. Ann Clin Psychiatry 1998;10:117-120.
89. Madhusoodanan S, Brenner R. Use of risperidone in psychosis associated with Huntington's disease. Am J Geriatr Psychiatry 1998;6:347-349.
90. Parsa MA, Szigethy E, Voci JM, Meltzer HY. Risperidone in treatment of choreoathetosis of Huntington's disease. J Clin Psychopharmacol 1997;17:134-135.
91. Reveley MA, Dursun SM, Andrews H. A comparative trial use of sulpiride and risperidone in Huntington's disease: a pilot study. J Psychopharmacol 1996;10:162-165.
92. Bonelli RM, Niederwieser G, Diez J, Koltringer P. Riluzole and olanzapine in Huntington's disease. Eur J Neurol 2002;9:183-184.
93. Jiménez-Jiménez FJ, de Toledo M, Puertas I, Barón M, Zurdo M, Barcenilla B. Olanzapine improves chorea in patients with Huntington's disease [In Spanish]. Rev Neurol 2002;35:524-525.
94. Bonelli RM, Niederwieser G, Tribl GG, Költringer P. High-dose olanzapine in Huntington's disease. Int Clin Psychopharmacol 2002;17:91-93.
95. Dipple H. The use of olanzapine for movement disorder in Huntington's disease: a first case report. J Neurol Neurosurg Psychiatry 1999;67:123-124.
96. Bonelli RM, Mahnert FA, Niederwieser G. Olanzapine for Huntington's disease: an open label study. Clin Neuropharmacol 2002;25:263-265.
97. Paleacu D, Anca M, Giladi N. Olanzapine in Huntington's disease. Acta Neurol Scand 2002;105:441-444.
98. Squitieri F, Cannella M, Piorcellini A, et al. Shortterm effects of olanzapine in Huntington's disease. Neuropsychiatry Neuropsychol Behav Neurol 2001;14:69-72.
99. Etchebehere EC, Lima MC, Passos W, et al. Brain SPECT imaging in Huntington's disease before and after therapy with olanzapine: case report. Arq Neuropsiquiatr 1999;57:863-866.
100. Quinn N, Marsden CD. A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia. J Neurol Neurosurg Psychiatry 1984;47:844-847.
101. Reveley MA, Dursun SM, Andrews H. A comparative trial use of sulpiride and risperidone in Huntington's disease: a pilot study. J Psychopharmacol 1996;10:162-165.
102. Reveley MA, Dursun SM, Andrews H. Improvement of abnormal saccadic eye movements in Huntington's disease by sulpiride: a case study. J Psychopharmacol 1994;8:262-265.
103. Bonelli RM, Niederwieser G. Quetiapine in Huntington's disease: a first case report. J Neurol.2002;249:1114-1115.
104. Seitz DP, Millson RC. Quetiapine in the management of psychosis secondary to Huntington's disease: a case report. Can J Psychiatry 2004;49:413.
105. Bonelli RM, Mayr BM, Niederwieser G, Reisecker F, Kapfhammer HP. Ziprasidone in Huntington's disease: the first case reports. J Psychopharmacol 2003;17:459-460.
106. Bonelli R, Niederwieser G, Lahousen T, Hofmann P. Zotepine in Huntington's disease. Hum Psychopharmacol Clin Exp 2003;18:227-229.
107. Ciammola A, Sassone J, Colciago C, et al. Aripiprazole in the treatment of Huntington's disease: a case series. Neuropsychiatr Dis Treat 2009;5:1-4.
108. Oulis P, Mourikis I, Konstantakopoulos G, Papageorgiou SG, Kouzoupis AV. Aripiprazole in the treatment of olanzapine-resistant psychotic and motor symptoms of Huntington's disease. J Neuropsychiatry Clin Neurosci 2010;22:352c.e4-352.e5.
109. Yavuz, KF, Ulusoy S, Alniak I. Aripiprazole treatment for choreoathetoid and psychotic symptoms of Huntington's disease. J Neuropsychiatry Clin Neurosci 2013;25:E31.
110. Lin WC, Chou YH. Aripiprazole effects on psychosis and chorea in a patient with Huntington's disease. Am J Psychiatry 2008;165:1207-1208.
111. Barr AN, Fischer JH, Koller WC, Spunt AL, Singhal A. Serum haloperidol concentration and choreiform movements in Huntington's disease. Neurology 1988;38:84-88.
112. Koller WC, Trimble J. The gait abnormality of Huntington's disease. Neurology 1985;35:1450-1454.
113. Girotti F, Carella F, Scigliano G, et al. Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington's disease. J Neurol Neurosurg Psychiatry 1984;47:848-852.
114. Girotti F, Carella F, Scigliano G, et al. Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington's disease. J Neurol Neurosurg Psychiatry 1984;47:848-852.
115. Terrence CF. Fluphenazine decanoate in the treatment of chorea:a double-blind study. Curr Ther Res Clin Exp 1976;20:177-183.
116. Whittier JR, Korenyi C. Effect of oral fluphenazine on Huntington's chorea. Int J Neuropsychiatry 1968;4:1-3.
117. Korenyi C, Whittier JR. Drug treatment in 117 cases of Huntington's disease with special reference to fluphenazine (Prolixin). Psychiatr Q 1967;41:203-210.
118. Arena R, Iudice A, Virgili P, Moretti P, Menchetti G. Huntington's disease: clinical effects of a short-term treatment with pimozide. Adv Biochem Psychopharmacol 1980;24:573-575.
119. Siegmund R, Schmeisser G, Heidrich R. Therapeutic experiences in the treatment of hyperkineses with the neuroleptic pimozide (Antalon, Orap) in the frame of Huntington chorea. Psychiatr Neurol Med Psychol (Leipz) 1982;34:307-308.
120. Deroover J, Baro F, Bourguignon RP, Smets P. Tiapride versus placebo: a double-blind comparative study in the management of Huntington's chorea. Curr Med Res Opin 1984;9:329-338.
121. Girotti F, Carella F, Scigliano G, et al. Effect of neuroleptic treatment on involuntary movements and motor performances in Huntington's disease. J Neurol Neurosurg Psychiatry. 1984;47:848-852.
122. Quinn N, Marsden CD. Tiapride in 12 Huntington's disease patients. J Neurol Neurosurg Psychiatry. 1985;48:292.
123. Brusa L, Orlacchio A, Moschella V, Iani C, Bernardi G, Mercuri NB. Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine. Mov Disord 2009;24:126-129.
124. Giménez-Roldán S, Mateo D. Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements [in Spanish]. Neurologia 1989;4:282-287.
125. Simpson MM, Goetz RR, Devlin MJ, Goetz SA, Walsh BT. Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods. J Clin Psychiatry 2001;62:694- 700.
126. Park SH. Off-label use of atypical antipsychotics: lack of evidence for their use in primary insomnia. Formulary Watch November 8, 2013.
127. Maglione M, Ruelaz Maher A, Hu J, et al. Off-label use of atypical antipsychotics: an update. Comparative Effectiveness Review No. 43. (Prepared by the Southern California Evidence-based Practice Center under Contract No. HHSA290-2007-10062-1.) Rockville, MD: Agency for Healthcare Research and Quality. [cited 2011 September]. Available from: www.effectivehealthcare.ahrq.gov/reports/final.cfm.
128. Peiris JB, Boralessa H, Lionel ND. Clonazepam in the treatment of choreiform activity. Med J Aust 1976;1:225-227.
129. De Tommaso M, Di Fruscolo O, Sciruicchio V, et al. Efficacy of levetiracetam in Huntington disease. Clin Neuropharmacol 2005;28:280-284.
130. Zesiewicz TA, Sullivan KL, Hauser RA, Sanchez-Ramos J. Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease. Mov Disord 2006;21:1998-2001.
131. Zesiewicz TA, Sanchez-Ramos J, Sullivan KL, Hauser RA. Levetiracetam-induced parkinsonism in a Huntington disease patient. Clin Neuropharmacol 2005;28:188-190.
132. Gatto EM, Roca CU, Etcheverry JL, Fadel D. Levetiracetam induced parkinsonism in a Huntington's disease patient [Comment on Clin Neuropharmacol 2005;28:188-190]. Clin Neuropharmacol 2006;29:303-304.
133. Cloud LJ, Rosenblatt A, Margolis RL, et al. Seizures in juvenile Huntington's disease: frequency and characterization in a multicenter cohort. Mov Disord 2012;27:1797-1800.
134. Caviness JN. Treatment of myoclonus. Neurotherapeutics 2014;11:188-200.
135. Pickrell WO, Lacey AS, Thomas RH, Smith PE, Rees MI. Weight change associated with antiepileptic drugs. J Neurol Neurosurg Psychiatry 2013;84:796-799.
136. Saft C, Lauter T, Kraus PH, et al. Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series. BMC Neurol 2006;6:11.
137. Bowden CL. New concepts in mood stabilization: evidence for the effectiveness of valproate and lamotrigine. Neuropsychopharmacology 1998;19:194-199.
138. Zoons E, Dijkgraaf MG, Dijk JM, van Schaik IN, Tijssen MA. Botulinum toxin as treatment for focal dystonia: a systematic review of the pharmaco-therapeutic and pharmaco-economic value. J Neurol 2012;259:2519-2526.
139. Tan E, Jankovic J, Ondo W. Bruxism in Huntington's disease. Mov Disord 2000;15:171-173.
140. Jongen P, Renier W, Gabreels F: Seven cases of Huntington's disease in childhood and levodopa induced improvement in the hypokinetic-rigid form. Clin Neurol Neurosurg 1980;82:251-261.
141. Reuter I, Hu M, Andrews T, Brooks D, Clough C, Chaudhuri K. Late onset levodopa-responsive Huntington's disease with minimal chorea masquerading as Parkinson plus syndrome. J Neurol Neurosurg Psychiatry 2000;68:238-241.
142. Low PA, Allsop JL, Halmagyi GM. Huntington's chorea: the rigid form (Westphal variant) treated with levodopa. Med J Aust 1974;1:393-394.
143. Low PA, Allsop JL. Huntington's chorea: the rigid form (Westphal variant) treated with l-DOPA: a case report. Proc Aust Assoc Neurol 1973;10:45-46.
144. Racette BA, Perlmutter JS. Levodopa responsive parkinsonism in an adult with Huntington's disease. J Neurol Neurosurg Psychiatry 1998;65:577-579.
145. Bonelli RM, Niederwieser G, Diez J, Gruber A, Költringer P. Pramipexole ameliorates neurologic and psychiatric symptoms in a Westphal variant of Huntington's disease. Clin Neuropharmacol 2002;25:58-60.
146. Magnet M, Bonelli R, Kapfhammer H. Amantadine in the akinetic-rigid variant of Huntington's disease. Ann Pharmacother 2004;38:1194-1196.
147. Holl AK, Wilkinson L, Painold A, et al. Combating depression in Huntington's disease: effective antidepressive treatment with venlafaxine XR. Int Clin Psychopharmacol 2010;25:46-50.
148. Beglinger LJ, Adams WH, Langbehn D, et al. Results of the citalopram to enhance cognition in Huntington disease trial. Mov Disord 2014;(29 Suppl 3):401-405.
149. De Marchi N, Daniele F, Ragone M. Fluoxetine in the treatment of Huntington's disease. Psychopharmacology 2001;153:264-266.
150. Royuela Rico A, Gil-Verona JA, Macias Fernández JA. A case of obsessive symptoms in Huntington's disease. Actas Esp Psiquiatr 2003;31:367-370.
151. Patzold T, Brune M. Obsessive compulsive disorder in Huntington disease: a case of isolated obsessions successfully treated with sertraline. Neuropsychiatry Neuropsychol Behav Neurol 2002;15:216-219.
152. Como PG, Rubin AJ, O'Brien CF, et al. A controlled trial of fluoxetine in non-depressed patients with Huntington's disease. Mov Disord 1997;12:397-401.
153. Ranen NG, Lipsey JR, Treisman G, Ross CA. Sertraline in the treatment of severe aggressiveness in Huntington's disease. J Neuropsychiatry Clin Neurosci 1996;8:338-340.
154. Bhandary AN, Masand PS. Buspirone in the management of disruptive behaviors due to Huntington's disease and other neurological disorders. Psychosomatics 1997;38:389-391.
155. Byrne A, Martin W, Hnatko G. Beneficial effects of buspirone therapy in Huntington's disease. Am J Psychiatry 1994;151:1097.
156. Findling RL. Treatment of aggression in juvenile-onset Huntington's disease with buspirone. Psychosomatics 1993;34:460-461.
157. Bonelli RM. Mirtazapine in suicidal Huntington's disease. Ann Pharmacother 2003;37:452.
158. Rosenblatt A. Neuropsychiatry of Huntington's disease. Dialogues Clin Neurosci 2007;9:191-197.
159. Grove Jr VE, Quintanilla J, DeVaney GT. Improvement of Huntington's disease with olanzapine and valproate. N Engl J Med 2000;343:973-974.
160. Shen YC. Lamotrigine in motor and mood symptoms of Huntington's disease. World J Biol Psychiatry 2008;9:147-149.
161. Danivas V, Moily NS, Thimmaiah R, Muralidharan K, Purushotham M, Muthane U, Jain S. Off label use of lithium in the treatment of Huntington's disease: a case series. Ind J Psychiatry 2013;55:81-83.
162. Leonard DP, Kidson MA, Shannon PJ, Brown J. Letter: double-blind trial of lithium carbonate and haloperidol in Huntington's chorea. Lancet 1974;2:1208-1209.
163. Raja M, Soleti F. Bentivoglio AR. Lithium treatment in patients with Huntington disease and suicidal behavior. J Clin Psychopharmacol 2013;336:819-821.
164. Alpay M, Koroshetz WJ. Quetiapine in the treatment of behavioral disturbances in patients with Huntington's disease. Psychosomatics 2006;47:70-72.
165. Blass DM, Steinberg M, Leroi I, Lyketsos CG. Successful multimodality treatment of severe behavioral disturbance in a patient with advanced Huntington's disease. Am J Psychiatry 2001;158:1966-1972.
166. Erdemoglu AK, Boratav C. Risperidone in chorea and psychosis of Huntington's disease. Eur J Neurol 2002;9:182-183.
167. Madhusoodanan S, Brenner R. Use of risperidone in psychosis associated with Huntington's disease. Am J Geriatr Psychiatry 1998;6:347-349.
168. Caserta MT, Sullivan E. Late-onset Huntington's disease masquerading as normal pressure hydrocephalus. J Neuropsychiatry Clin Neurosci 2009;21:97-98.
169. Lin W-C, Chou Y-H. Aripiprazole effects on psychosis and chorea in a patient with Huntington's disease. Am J Psychiatry 2008;165:1207-1208.
170. Lyketsos CG, Rosenblatt A, Rabins PV. Forgotten frontal lobe syndrome or "executive dysfunction syndrome." Psychosomatics 2004;45:247-225.
171. Stewart JT, Mounts ML, Clark Jr RL. Aggressive behavior in Huntington's disease: treatment with propranolol. J Clin Psychiatry 1987;48:106-108.
172. Ranen NG, Peyser CE, Folstein SE. ECT as a treatment for depression in Huntington's disease. J Neuropsychiatry Clin Neurosci 1994;6:154-159.
173. Lewis CF, DeQuardo JR, Tandon R. ECT in genetically confirmed Huntington's disease. J Neuropsychiatry Clin Neurosci 1996;8:209-210.
174. Beglinger LJ, Adams WH, Paulson H, et al. Randomized controlled trial of atomoxetine for cognitive dysfunction in early Huntington disease. J Clin Psychopharmacol 2009;29:484e7.
175. Cubo E, Shannon KM, Tracy D, et al. Effect of donepezil on motor and cognitive function in Huntington disease. Neurology 2006;67:1268-1271.
176. Fernandez HH, Friedman JH, Grace J, Beason-Hazen S. Donepezil for Huntington's disease. Mov Disord 2000;15:173-176.
177. Ondo WG, Mejia NI, Hunter CB. A pilot study of the clinical efficacy and safety of memantine for Huntington's disease. Parkinsonism Relat Disord 2007;13:453-454.
178. Blackwell AD, Paterson NS, Barker RA, Robbins TW, Sahakian BJ. The effects of modafinil on mood and cognition in Huntington's disease. Psychopharmacology (Berl) 2008;199:29-36.
179. Rot U, Kobal J, Sever A, Pirtosek Z, Mesec A. Rivastigmine in the treatment of Huntington's disease. Eur J Neurol 2002;9:689-690.
180. de Tommaso M, Difruscolo O, Sciruicchio V, Specchio N, Livrea P. Two years' follow-up of rivastigmine treatment in Huntington disease. Clin Neuropharmacol 2007;30:43-46.
181. Royall DR, Mahurin RK. EXIT 25, QED, and DSM-IV: very early Alzheimer's disease. J Neuropsychiatry Clin Neurosci 1994;6:62-64.